CMRX Chimerix Inc.

1.99
-0.02  -1%
Previous Close 2.01
Open 1.99
Price To Book 1.09
Market Cap 122,150,703
Shares 61,382,263
Volume 218,659
Short Ratio
Av. Daily Volume 587,000
Stock charts supplied by TradingView

NewsSee all news

  1. Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

    DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced

  2. Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update

    – Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase 2 Meeting for Dociparstat (DSTAT) and

  3. Chimerix to Present at Upcoming Investor Conferences

    DURHAM, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced

  4. Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

    Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit

  5. Chimerix to Present at 2019 Cantor Global Healthcare Conference

    DURHAM, N.C., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor Global Healthcare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA due 2020.
Oral Brincidofovir
Smallpox
Phase 2 trial discontinued - May 9, 2019.
IV Brincidofovir
Adult allo-HCT recipients with Adenovirus
Phase 2 trial discontinued - May 9, 2019.
Oral Brincidofovir - AdAPT Study
Allogeneic hematopoietic stem cell transplant (HCT) recipients with adenovirus (AdV)
Phase 3 interim analysis released May 2016. Final data released February 22, 2017.
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SURPASS
Cytomegalovirus (CMV) infection
Phase 3 endpoints not met December 2015
Brincidofovir - SUPPRESS
Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN
Cytomegalovirus (CMV) infection
Phase 1 data at European Society for Clinical Virology.
CMX521
Norovirus
Phase 3 trial to be initiated mid-2020.
DSTAT (CX-01)
Acute Myeloid Leukemia (AML)

Latest News

  1. Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

    DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced

  2. Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update

    – Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase 2 Meeting for Dociparstat (DSTAT) and

  3. Chimerix to Present at Upcoming Investor Conferences

    DURHAM, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced

  4. Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

    Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit

  5. Chimerix to Present at 2019 Cantor Global Healthcare Conference

    DURHAM, N.C., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor Global Healthcare